Lupin unveils generic version of Lipitor Tablets

Published On 2020-09-29 07:00 GMT   |   Update On 2023-10-17 12:03 GMT

Mumbai, Baltimore: Pharma major, Lupin Limited, has recently announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier. The product will be manufactured at Lupin's Nagpur facility in India. Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is...

Login or Register to read the full article

Mumbai, Baltimore: Pharma major, Lupin Limited, has recently announced the launch of Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, having received an approval from the United States Food and Drug Administration (U.S. FDA) earlier.

The product will be manufactured at Lupin's Nagpur facility in India.

Atorvastatin Calcium Tablets USP, 10 mg, 20 mg, 40 mg, and 80 mg, is the generic equivalent of Lipitor Tablets, 10 mg, 20 mg, 40 mg and 80 mg, of Pfizer Inc., and indicated to lower cholesterol in blood for adults and children over 10 years of age.

Atorvastatin is also prescribed to lower the risk of heart attack and stroke in patients with cardiovascular diseases, diabetes and other risk factors such as eye problems, kidney diseases or high blood pressure.

Atorvastatin Calcium Tablets USP (RLD: Lipitor) had annual sales of approximately USD 559 million in the U.S. (IQVIA MAT July 2020).

Read also: Lupin unveils bipolar disorder drug Divalproex Sodium ER Tablets in US

Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.

The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.






Tags:    

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News